Request a Proposal
Welcome to Rapport, containing tips, truths, news and views, blogs, tweets, articles and films covering a range of topics currently affecting Research Partnership and the pharma market research world.
  • Posted by Helen Parfitt, Mariel Metcalfe and Mark Hollis
  • March 22, 2019
  • Webinars

Navigating new frontiers: Ways to find space in the future RA market

Navigating new frontiers: Ways to find space in the future RA market

In partnership with pharmaphorum

Rheumatoid arthritis (RA) has been a major growth driver for the pharmaceutical industry over the last 15 years, led by AbbVie’s blockbuster anti-TNF inhibitor treatment Humira (adalimumab).

read more »

  • Posted by Allison Fleetwood
  • June 24, 2014
  • News

Quarter of RA biologics patients receiving treatment without a traditional DMARD

Quarter of RA biologics patients receiving treatment without a traditional DMARD

With 25% of biologic patients receiving a drug without a traditional DMARD, what are the clinical characteristics which influence physicians’ decision to use biologics without a concomitant traditional DMARD?

With 25% of biologic patients receiving a drug without a traditional DMARD, what are the clinical characteristics which influence physicians’ decision to use biologics without a concomitant traditional DMARD?
EULAR guidelines for the management of rheumatoid arthritis (RA) with synthetic and biological disease-modifying drugs recommend that all biologics should be used preferentially in combination with methotrexate (MTX) or other traditional DMARDs, and that these represent an anchor treatment in RA.

read more »